General Court confirms likelihood of confusion between pharma marks

European Union

In Bionecs GmbH v OHIM, the General Court has upheld a decision of the OHIM Board of Appeal finding that there was a likelihood of confusion between the word marks BIONECS and BIONECT for goods in Class 5. Among other things, the court held that the goods covered by the marks fell within the field of health, and that the board had been right to find that the nature and purpose of the goods were the same.

Get unlimited access to all WTR content